Christophe Van Dijck

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
A novel recombinant interferon-α B/Dhybrid was applied to assess tolerability, antiviraleffect, and biological activity in chronic hepatitis B.The study was designed as an open nonrandomized trial. Treatment comprised a two-week run-in phasewith 16 MU three times a week followed by 14 weeks with64 MU three times a week (or 48 MU if toxicity occurredwith 64(More)
  • 1